Assessment of peripheral blood protein glycosylation has recently become scalable, providing a new domain for biomarker research.
Klaus Lindpaintner
Advertisement
Klaus Lindpaintner, MD, MPH is chief scientific officer and distinguished scientist at InterVenn BioSciences.
Articles by Klaus Lindpaintner
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5